Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer-Reference-Cited by-同舟云学术

Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer

Published:2005-06 Issue:4 Volume:21 Page:333-347
ISSN:0265-6736
Container-title:International Journal of Hyperthermia
language:en
Short-container-title:International Journal of Hyperthermia

Author:

Alvarez Secord A.,Jones E. L.,Hahn C. A.,Petros W. P.,Yu D.,Havrilesky L. J.,Soper J. T.,Berchuck A.,Spasojevic I.,Clarke-Pearson D. L.,Prosnitz L. R.,Dewhirst M. W.

Publisher

Informa UK Limited

Subject

Cancer Research,Physiology (medical),Physiology

Link

http://www.tandfonline.com/doi/pdf/10.1080/02656730500110155

Reference26 articles.

1. Platinum-Resistant and Refractory Ovarian Cancer

2. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

3. Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Controlling the biodistribution and clearance of nanomedicines;Nature Reviews Bioengineering;2023-12-20

2. Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies;International Journal of Pharmaceutics;2023-04

3. Real World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radio(chemo)therapy;Cancers;2023-02-15

4. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation;Journal of Controlled Release;2022-05

5. Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment;Cancers;2022-01-26